Arcturus Therapeutics (ARCT) Competitors $10.57 +0.39 (+3.83%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$10.86 +0.29 (+2.74%) As of 04/15/2025 05:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipShort InterestTrendsBuy This Stock ARCT vs. SNDX, WVE, COLL, ELVN, DYN, GPCR, ETNB, CMRX, CDMO, and RCUSShould you be buying Arcturus Therapeutics stock or one of its competitors? The main competitors of Arcturus Therapeutics include Syndax Pharmaceuticals (SNDX), Wave Life Sciences (WVE), Collegium Pharmaceutical (COLL), Enliven Therapeutics (ELVN), Dyne Therapeutics (DYN), Structure Therapeutics (GPCR), 89bio (ETNB), Chimerix (CMRX), Avid Bioservices (CDMO), and Arcus Biosciences (RCUS). These companies are all part of the "pharmaceutical products" industry. Arcturus Therapeutics vs. Syndax Pharmaceuticals Wave Life Sciences Collegium Pharmaceutical Enliven Therapeutics Dyne Therapeutics Structure Therapeutics 89bio Chimerix Avid Bioservices Arcus Biosciences Arcturus Therapeutics (NASDAQ:ARCT) and Syndax Pharmaceuticals (NASDAQ:SNDX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, valuation, institutional ownership, profitability, analyst recommendations and community ranking. Do analysts recommend ARCT or SNDX? Arcturus Therapeutics presently has a consensus target price of $59.20, suggesting a potential upside of 460.08%. Syndax Pharmaceuticals has a consensus target price of $36.20, suggesting a potential upside of 219.51%. Given Arcturus Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Arcturus Therapeutics is more favorable than Syndax Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arcturus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13Syndax Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.90 Do insiders & institutionals believe in ARCT or SNDX? 94.5% of Arcturus Therapeutics shares are owned by institutional investors. 15.3% of Arcturus Therapeutics shares are owned by company insiders. Comparatively, 4.1% of Syndax Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Is ARCT or SNDX more profitable? Syndax Pharmaceuticals has a net margin of 0.00% compared to Arcturus Therapeutics' net margin of -36.39%. Arcturus Therapeutics' return on equity of -22.39% beat Syndax Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Arcturus Therapeutics-36.39% -22.39% -14.81% Syndax Pharmaceuticals N/A -64.34%-57.72% Does the MarketBeat Community prefer ARCT or SNDX? Arcturus Therapeutics received 56 more outperform votes than Syndax Pharmaceuticals when rated by MarketBeat users. Likewise, 66.32% of users gave Arcturus Therapeutics an outperform vote while only 65.38% of users gave Syndax Pharmaceuticals an outperform vote. CompanyUnderperformOutperformArcturus TherapeuticsOutperform Votes44766.32% Underperform Votes22733.68% Syndax PharmaceuticalsOutperform Votes39165.38% Underperform Votes20734.62% Which has more volatility & risk, ARCT or SNDX? Arcturus Therapeutics has a beta of 3.41, indicating that its share price is 241% more volatile than the S&P 500. Comparatively, Syndax Pharmaceuticals has a beta of 1.28, indicating that its share price is 28% more volatile than the S&P 500. Does the media refer more to ARCT or SNDX? In the previous week, Arcturus Therapeutics had 1 more articles in the media than Syndax Pharmaceuticals. MarketBeat recorded 8 mentions for Arcturus Therapeutics and 7 mentions for Syndax Pharmaceuticals. Syndax Pharmaceuticals' average media sentiment score of 0.65 beat Arcturus Therapeutics' score of 0.47 indicating that Syndax Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcturus Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Syndax Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher earnings and valuation, ARCT or SNDX? Arcturus Therapeutics has higher revenue and earnings than Syndax Pharmaceuticals. Arcturus Therapeutics is trading at a lower price-to-earnings ratio than Syndax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArcturus Therapeutics$138.39M2.07-$29.73M-$3.01-3.51Syndax Pharmaceuticals$23.68M41.17-$209.36M-$3.73-3.04 SummaryArcturus Therapeutics beats Syndax Pharmaceuticals on 14 of the 19 factors compared between the two stocks. Remove Ads Get Arcturus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ARCT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARCT vs. The Competition Export to ExcelMetricArcturus TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$286.66M$6.33B$5.33B$7.57BDividend YieldN/A3.24%5.11%4.32%P/E Ratio-4.766.7921.7317.81Price / Sales2.07225.96379.2094.61Price / CashN/A65.6738.1534.64Price / Book1.015.866.464.00Net Income-$29.73M$141.86M$3.20B$247.23M7 Day Performance7.64%4.50%2.85%1.45%1 Month Performance-24.93%-12.65%-8.55%-6.24%1 Year Performance-64.92%-11.06%10.46%0.60% Arcturus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARCTArcturus Therapeutics2.7545 of 5 stars$10.57+3.8%$59.20+460.1%-63.9%$286.66M$138.39M-4.76180SNDXSyndax Pharmaceuticals3.3478 of 5 stars$11.01-2.1%$36.20+228.8%-47.6%$947.34M$23.68M-3.03110Gap DownWVEWave Life Sciences4.1775 of 5 stars$5.80-3.8%$22.60+289.7%+9.4%$890.22M$108.30M-5.23240Short Interest ↑Analyst RevisionCOLLCollegium Pharmaceutical4.0797 of 5 stars$27.38-2.7%$43.60+59.2%-22.8%$879.77M$631.45M11.80210News CoverageELVNEnliven Therapeutics2.5632 of 5 stars$17.87-4.4%$38.75+116.8%-14.5%$875.70MN/A-9.4150News CoverageDYNDyne Therapeutics3.5747 of 5 stars$7.49-9.5%$47.46+533.7%-69.1%$847.28MN/A-2.10100Positive NewsGPCRStructure Therapeutics2.5757 of 5 stars$14.31-5.4%$81.29+468.0%-49.8%$820.58MN/A-19.34136News CoverageETNB89bio2.5885 of 5 stars$5.49-4.9%$27.56+401.9%-36.2%$801.45MN/A-1.8940Short Interest ↑News CoverageHigh Trading VolumeCMRXChimerix2.9193 of 5 stars$8.52-0.1%$8.53+0.2%+834.8%$799.21M$212,000.00-9.0690CDMOAvid Bioservices0.7966 of 5 stars$12.50+0.1%$12.25-2.0%+83.8%$799.18M$139.91M-5.23320High Trading VolumeRCUSArcus Biosciences2.4672 of 5 stars$7.28+5.9%$30.25+315.8%-50.9%$764.88M$258M-2.31500High Trading Volume Remove Ads Related Companies and Tools Related Companies Syndax Pharmaceuticals Alternatives Wave Life Sciences Alternatives Collegium Pharmaceutical Alternatives Enliven Therapeutics Alternatives Dyne Therapeutics Alternatives Structure Therapeutics Alternatives 89bio Alternatives Chimerix Alternatives Avid Bioservices Alternatives Arcus Biosciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ARCT) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredDOGE tax surpriseElon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax auth...Altimetry | SponsoredAmazon ShockerJeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcturus Therapeutics Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcturus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ARCT Stock Free ARCT Stock Alerts